Postgraduate Symposium: The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA

Proceedings of the Nutrition Society

Volumn 69, Issue 2, 2010, Pages 232-243

  Oliver, Elizabeth ^a,b   McGillicuddy, Fiona ^a   Phillips, Catherine ^a   Toomey, Sinead ^a   Roche, Helen M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Adipose tissue macrophages; Inflammation; Long chain n 3 PUFA; Obesity induced insulin resistance

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ARACHIDONIC ACID; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; CYTOKINE; DOCOSAHEXAENOIC ACID; FISH OIL; GLUCOSE; GLUCOSE TRANSPORTER 4; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LINOLEIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TYROSINE; TRANSCRIPTION FACTOR;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL INFILTRATION; CELL INTERACTION; CONFERENCE PAPER; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DOWN REGULATION; DRUG EFFECT; EUROPE; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; MACROPHAGE; METABOLIC SYNDROME X; MOLECULAR INTERACTION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PSORIASIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; WORLD HEALTH ORGANIZATION; ANIMAL; IMMUNOLOGY; METABOLISM; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; EICOSANOIDS; FATTY ACIDS, OMEGA-3; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; MACROPHAGES; OBESITY; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 77955502543     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665110000042     Document Type: Conference Paper

References (113)

1. Kopelman PG (2000) Obesity as a medical problem. Nature 404, 635-643.
2. World Health Organization (2006) European Ministerial Conference on Counteracting Obesity Diet and Physical Activity for Health. Copenhagen, Denmark: WHO Regional Office for Europe; available at http://www.euro.who.int/ document/E90143.pdf
3. Liu LL, Lawrence JM, Davis C et al. (2009) Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth Study. Pediatr Diabetes (Epublication ahead of print version; doi: 10.1111/j.1399-5448. 2009.00519.x).
4. Nguyen MT, Satoh H, Favelyukis S et al. (2005) JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 280, 35361-35371. (Pubitemid 41532725)
5. Xu H, Barnes GT, Yang Q et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112, 1821-1830. (Pubitemid 38063705)
6. Weisberg SP, McCann D, Desai M et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112, 1796-1808. (Pubitemid 38063703)
7. Peraldi P, Hotamisligil GS, Buurman WA et al. (1996) Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 271, 13018-13022. (Pubitemid 26175877)
8. Lumeng CN, Deyoung SM & Saltiel AR (2007) Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol Endocrinol Metab 292, E166-E174.
9. Browning LM (2003) n-3 Polyunsaturated fatty acids, inflammation and obesity-related disease. Proc Nutr Soc 62, 447-453. (Pubitemid 36841620)
10. Steinberger J & Daniels SR (2003) Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 107, 1448-1453. (Pubitemid 36350747)
11. Colditz GA, Willett WC, Rotnitzky A et al. (1995) Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122, 481-486.
12. Chan JM, Rimm EB, Colditz GA et al. (1994) Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17, 961-969.
13. Kissebah AH, Vydelingum N, Murray R et al. (1982) Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 54, 254-260. (Pubitemid 12006594)
14. Kahn BB & Rossetti L (1998) Type 2 diabetes - who is conducting the orchestra? Nat Genet 20, 223-225. (Pubitemid 28507661)
15. International Diabetes Federation (2009) Diabetes atlas: Diabetic complications. http://da3.diabetesatlas.org/index711b.html
16. Davies MJ (2005) Post-prandial hyperglycaemia and prevention of cardiovascular disease. Diabet Med 22, Suppl. 1, 6-9. (Pubitemid 40188300)
17. Kahn CR (1985) The molecular mechanism of insulin action. Annu Rev Med 36, 429-451.
18. Reaven GM (1995) Pathophysiology of insulin resistance in human disease. Physiol Rev 75, 473-486.
19. Yenush L & White MF (1997) The IRS-signalling system during insulin and cytokine action. Bioessays 19, 491-500. (Pubitemid 27299497)
20. Alessi DR & Cohen P (1998) Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8, 55-62. (Pubitemid 28122141)
21. Khan AH & Pessin JE (2002) Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia 45, 1475-1483.
22. Cross DA, Alessi DR, Cohen P et al. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789. (Pubitemid 26004411)
23. Bourlier V, Zakaroff-Girard A, Miranville A et al. (2008) Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 117, 806-815. (Pubitemid 351640682)
24. O'Brien RM, Streeper RS, Ayala JE et al. (2001) Insulinregulated gene expression. Biochem Soc Trans 29, 552-558.
25. Furtado LM, Somwar R, Sweeney G et al. (2002) Activation of the glucose transporter GLUT4 by insulin. Biochem Cell Biol 80, 569-578. (Pubitemid 36124818)
26. Aguirre V, Uchida T, Yenush L et al. (2000) The c-Jun. NH (2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser (307). J Biol Chem 275, 9047-9054. (Pubitemid 30180265)
27. Aguirre V, Werner ED, Giraud J et al. (2002) Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277, 1531-1537. (Pubitemid 34968910)
28. Somwar R, Koterski S, Sweeney G et al. (2002) A dominant-negative p38 MAPK mutant and novel selective inhibitors of p38 MAPK reduce insulin-stimulated glucose uptake in 3T3-L1 adipocytes without affecting GLUT4 translocation. J Biol Chem 277, 50386-50395. (Pubitemid 36042189)
29. Kim JB, Sarraf P, Wright M et al. (1998) Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 101, 1-9. (Pubitemid 28058896)
30. Shimomura I, Bashmakov Y, Ikemoto S et al. (1999) Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 96, 13656-13661.
31. Foretz M, Guichard C, Ferre P et al. (1999) Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci USA 96, 12737-12742. (Pubitemid 29513572)
32. Kops GJ & Burgering BM (1999) Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med 77, 656-665.
33. Jones JR, Barrick C, Kim KA et al. (2005) Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci USA 102, 6207-6212. (Pubitemid 40594279)
34. Trayhurn P & Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92, 347-355. (Pubitemid 40277057)
35. Samad F, Yamamoto K, Pandey M et al. (1997) Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med 3, 37-48. (Pubitemid 27142523)
36. Hotamisligil GS, Shargill NS & Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87-91.
37. Fried SK, Bunkin DA & Greenberg AS (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83, 847-850.
38. Perreault M & Marette A (2001) Targeted disruption of inducible nitric oxide synthase protects against obesitylinked insulin resistance in muscle. Nat Med 7, 1138-1143. (Pubitemid 33010023)
39. Visser M, Bouter LM, McQuillan GM et al. (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282, 2131-2135.
40. Sartipy P & Loskutoff DJ (2003) Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 100, 7265-7270. (Pubitemid 36706427)
41. Samad F, Yamamoto K & Loskutoff DJ (1996) Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 97, 37-46. (Pubitemid 26021692)
42. Arita Y, Kihara S, Ouchi N et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257, 79-83. (Pubitemid 29299050)
43. Tomas E, Tsao TS, Saha AK et al. (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99, 16309-16313. (Pubitemid 35462791)
44. Cancello R, Henegar C, Viguerie N et al. (2005) Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54, 2277-2286. (Pubitemid 41134253)
45. Cancello R, Tordjman J, Poitou C et al. (2006) Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 55, 1554-1561. (Pubitemid 44324107)
46. Surmi BK & Hasty AH (2008) Macrophage infiltration into adipose tissue: initiation, propagation and remodeling. Future Lipidol 3, 545-556.
47. Hosogai N, Fukuhara A, Oshima K et al. (2007) Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56, 901-911. (Pubitemid 46525054)
48. Ye J, Gao Z, Yin J et al. (2007) Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 293, E1118-E1128. (Pubitemid 47535846)
49. Voros G, Maquoi E, Demeulemeester D et al. (2005) Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology 146, 4545-4554. (Pubitemid 41324053)
50. Pang C, Gao Z, Yin J et al. (2008) Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity. Am J Physiol Endocrinol Metab 295, E313-E322.
51. Wang F, Li SS, Segersvard R et al. (2007) Hypoxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energy homeostasis. Am J Pathol 170, 469-477. (Pubitemid 47339384)
52. Wang W & Zhang J (2008) Induction of renoprotective gene expression by hypoxia-inducible transcription factor-1alpha ameliorates renal damage. Med Hypotheses 70, 948-950. (Pubitemid 351400708)
53. Cinti S, Mitchell G, Barbatelli G et al. (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46, 2347-2355. (Pubitemid 41532523)
54. Bruun JM, Lihn AS, Pedersen SB et al. (2005) Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT) : implication of macrophages resident in the AT. J Clin Endocrinol Metab 90, 2282-2289.
55. Christiansen T, Richelsen B & Bruun JM (2005) Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond) 29, 146-150. (Pubitemid 40065478)
56. Weisberg SP, Hunter D, Huber R et al. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116, 115-124. (Pubitemid 43121796)
57. Savill J, Dransfield I, Gregory C et al. (2002) A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2, 965-975. (Pubitemid 37323217)
58. Lumeng CN, Bodzin JL & Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117, 175-184.
59. Gordon S & Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5, 953-964. (Pubitemid 41746764)
60. Mantovani A, Sica A, Sozzani S et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25, 677-686. (Pubitemid 39457982)
61. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH et al. (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447, 1116-1120.
62. Zeyda M, Farmer D, Todoric J et al. (2007) Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 31, 1420-1428. (Pubitemid 47339934)
63. Uysal KT, Wiesbrock SM, Marino MW et al. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389, 610-614.
64. Rui L, Aguirre V, Kim JK et al. (2001) Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 107, 181-189. (Pubitemid 32096834)
65. Rotter V, Nagaev I & Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278, 45777-45784. (Pubitemid 37432722)
66. Ueki K, Kondo T, Tseng YH et al. (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 101, 10422-10427. (Pubitemid 38924941)
67. Shi H, Cave B, Inouye K et al. (2006) Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. Diabetes 55, 699-707. (Pubitemid 43343226)
68. Gual P, Gremeaux T, Gonzalez T et al. (2003) MAP kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor substrate-1 on serine residues 307, 612 and 632. Diabetologia 46, 1532-1542. (Pubitemid 37518574)
69. Jager J, Gremeaux T, Cormont M et al. (2007) Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 148, 241-251. (Pubitemid 46021456)
70. Christman JW, Lancaster LH & Blackwell TS (1998) Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 24, 1131-1138.
71. Chen F, Castranova V, Shi X et al. (1999) New insights into the role of nuclear factor-kappa B, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45, 7-17. (Pubitemid 29036378)
72. Arkan MC, Hevener AL, Greten FR et al. (2005) IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11, 191-198. (Pubitemid 40321355)
73. Geusens P, Wouters C, Nijs J et al. (1994) Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. Arthritis Rheum 37, 824-829. (Pubitemid 24184532)
74. Broughton KS, Johnson CS, Pace BK et al. (1997) Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. Am J Clin Nutr 65, 1011-1017.
75. Belluzzi A, Brignola C, Campieri M et al. (1996) Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 334, 1557-1560. (Pubitemid 26177482)
76. Mayser P, Mrowietz U, Arenberger P et al. (1998) Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol 38, 539-547. (Pubitemid 28182921)
77. Sijben JW & Calder PC (2007) Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc Nutr Soc 66, 237-259.
78. Eaton SB & Konner M (1985) Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med 312, 283-289. (Pubitemid 15199367)
79. Simopoulos AP, Norman HA & Gillaspy JE (1995) Purslane in human nutrition and its potential for world agriculture. World Rev Nutr Diet 77, 47-74.
80. Calder PC (2006) n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83, 1505S-1519S. (Pubitemid 44713092)
81. Bagga D, Wang L, Farias-Eisner R et al. (2003) Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA 100, 1751-1756. (Pubitemid 36254520)
82. Lewis RA, Austen KF & Soberman RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 323, 645-655.
83. Tilley SL, Coffman TM & Koller BH (2001) Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 108, 15-23.
84. Simopoulos AP (2000) Human requirement for N-3 polyunsaturated fatty acids. Poult Sci 79, 961-970.
85. Jump DB (2002) Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol 13, 155-164. (Pubitemid 34280767)
86. Schmitz G & Ecker J (2008) The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 47, 147-155.
87. Benatti P, Peluso G, Nicolai R et al. (2004) Polyunsaturated fatty acids: biochemical, nutritional and epigenetic properties. J Am Coll Nutr 23, 281-302. (Pubitemid 39096388)
88. Jump DB & Clarke SD (1999) Regulation of gene expression by dietary fat. Annu Rev Nutr 19, 63-90. (Pubitemid 29380597)
89. Jiang C, Ting AT & Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86. (Pubitemid 28079219)
90. Poynter ME & Daynes RA (1998) Peroxisome proliferatoractivated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappa B signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273, 32833-32841.
91. Ricote M, Li AC, Willson TM et al. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82. (Pubitemid 28079218)
92. Jackson SM, Parhami F, Xi XP et al. (1999) Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19, 2094-2104. (Pubitemid 29422240)
93. Marx N, Bourcier T, Sukhova GK et al. (1999) PPAR-gamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR-gamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19, 546-551. (Pubitemid 29135154)
94. Takano H, Nagai T, Asakawa M et al. (2000) Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 87, 596-602.
95. Wang AC, Dai X, Luu B et al. (2001) Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol 24, 688-693. (Pubitemid 32550590)
96. Xu HE, Lambert MH, Montana VG et al. (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 98, 13919-13924. (Pubitemid 33115999)
97. Chinetti G, Fruchart JC & Staels B (2000) Peroxisome proliferator-activated receptors (PPARs) : nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49, 497-505. (Pubitemid 32294402)
98. Delerive P, Fruchart JC & Staels B (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169, 453-459. (Pubitemid 32536978)
99. Weldon SM, Mullen AC, Loscher CE et al. (2007) Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J Nutr Biochem 18, 250-258.
100. Todoric J, Loffler M, Huber J et al. (2006) Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49, 2109-2119. (Pubitemid 44168479)
101. Lee JY, Sohn KH, Rhee SH et al. (2001) Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 276, 16683-16689. (Pubitemid 37411459)
102. Shi H, Kokoeva MV, Inouye K et al. (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116, 3015-3025. (Pubitemid 44684486)
103. Lee JY, Plakidas A, Lee WH et al. (2003) Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 44, 479-486. (Pubitemid 37279695)
104. Coenen KR, Gruen ML, Lee-Young RS et al. (2009) Impact of macrophage toll-like receptor 4 deficiency on macrophage infiltration into adipose tissue and the artery wall in mice. Diabetologia 52, 318-328.
105. Kromann N & Green A (1980) Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med Scand 208, 401-406. (Pubitemid 11162992)
106. Adler AI, Boyko EJ, Schraer CD et al. (1994) Lower prevalence of impaired glucose tolerance and diabetes associated with daily seal oil or salmon consumption among Alaska Natives. Diabetes Care 17, 1498-1501.
107. Schraer CD, Risica PM, Ebbesson SO et al. (1999) Low fasting insulin levels in Eskimos compared to American Indians: are Eskimos less insulin resistant? Int J Circumpolar Health 58, 272-280.
108. Hu FB, Cho E, Rexrode KM et al. (2003) Fish and longchain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 107, 1852-1857. (Pubitemid 36444124)
109. Meyer KA, Kushi LH, Jacobs DR Jr et al. (2001) Dietary fat and incidence of type 2 diabetes in older Iowa women. Diabetes Care 24, 1528-1535. (Pubitemid 33716444)
110. Kesavulu MM, Kameswararao B, Apparao C et al. (2002) Effect of omega-3 fatty acids on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. Diabetes Metab 28, 20-26. (Pubitemid 34168746)
111. Storlien LH, Jenkins AB, Chisholm DJ et al. (1991) Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes 40, 280-289.
112. Taouis M, Dagou C, Ster C et al. (2002) N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle. Am J Physiol Endocrinol Metab 282, E664-E671. (Pubitemid 34654784)
113. Aguilera AA, Diaz GH, Barcelata ML et al. (2004) Effects of fish oil on hypertension, plasma lipids, and tumor necrosis factor-alpha in rats with sucroseinduced metabolic syndrome. J Nutr Biochem 15, 350-357.